NO965012L - Farmasöytisk preparat som omfatter glukagon - Google Patents

Farmasöytisk preparat som omfatter glukagon

Info

Publication number
NO965012L
NO965012L NO965012A NO965012A NO965012L NO 965012 L NO965012 L NO 965012L NO 965012 A NO965012 A NO 965012A NO 965012 A NO965012 A NO 965012A NO 965012 L NO965012 L NO 965012L
Authority
NO
Norway
Prior art keywords
glucagon
pharmaceutical composition
dipeptide
excipient
optionally
Prior art date
Application number
NO965012A
Other languages
English (en)
Other versions
NO965012D0 (no
Inventor
Troels Kornfelt
Henrik Rasmussen
Flemming Steen Jensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO965012L publication Critical patent/NO965012L/no
Publication of NO965012D0 publication Critical patent/NO965012D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytisk preparat som om- fatter glukagon og en stabiliserende mengde av en farmasøytisk akseptabel amfolytt, spesielt en aminosyre eller et dipeptid, eller en blanding derav, og eventuelt en eksipiens, som er sta- bilt i langvarige tidsrom.
NO965012A 1994-05-26 1996-11-25 Farmasöytisk preparat som omfatter glukagon NO965012D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK59094 1994-05-26
PCT/DK1995/000208 WO1995032730A1 (en) 1994-05-26 1995-05-26 A pharmaceutical preparation comprising glucagon

Publications (2)

Publication Number Publication Date
NO965012L true NO965012L (no) 1996-11-25
NO965012D0 NO965012D0 (no) 1996-11-25

Family

ID=8095292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965012A NO965012D0 (no) 1994-05-26 1996-11-25 Farmasöytisk preparat som omfatter glukagon

Country Status (12)

Country Link
US (1) US5652216A (no)
EP (1) EP0760677B1 (no)
JP (1) JP3295430B2 (no)
AT (1) ATE205090T1 (no)
AU (1) AU694229B2 (no)
CA (1) CA2191317A1 (no)
DE (1) DE69522562T2 (no)
DK (1) DK0760677T3 (no)
ES (1) ES2163511T3 (no)
FI (1) FI964682L (no)
NO (1) NO965012D0 (no)
WO (1) WO1995032730A1 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1999047160A1 (en) * 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DK3300721T4 (da) * 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
WO2009048462A1 (en) 2007-10-09 2009-04-16 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
WO2005110394A1 (ja) * 2004-05-19 2005-11-24 Ajinomoto Co., Inc. 糖尿病治療薬
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
MX2007005521A (es) * 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
CA2702799A1 (en) 2007-10-25 2009-04-30 Dexcom, Inc. Systems and methods for processing sensor data
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
EP2461818B1 (en) 2009-08-03 2018-10-17 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
DK2490708T3 (da) 2009-10-22 2013-04-15 Biodel Inc Stabiliserede glucagon-opløsninger
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2012012460A1 (en) * 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2015027173A1 (en) * 2013-08-22 2015-02-26 Zp Opco, Inc. Stable glucagon peptide formulations
US9782344B2 (en) * 2013-08-22 2017-10-10 Zp Opco, Inc. Stable glucagon peptide formulations
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
CA2993215C (en) * 2015-07-02 2023-10-31 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
KR20240036128A (ko) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat

Also Published As

Publication number Publication date
JPH10500696A (ja) 1998-01-20
EP0760677B1 (en) 2001-09-05
DK0760677T3 (da) 2001-12-31
FI964682A7 (fi) 1997-01-20
WO1995032730A1 (en) 1995-12-07
EP0760677A1 (en) 1997-03-12
AU2560695A (en) 1995-12-21
FI964682L (fi) 1997-01-20
ATE205090T1 (de) 2001-09-15
AU694229B2 (en) 1998-07-16
CA2191317A1 (en) 1995-12-07
DE69522562T2 (de) 2002-07-11
NO965012D0 (no) 1996-11-25
ES2163511T3 (es) 2002-02-01
DE69522562D1 (de) 2001-10-11
US5652216A (en) 1997-07-29
JP3295430B2 (ja) 2002-06-24
FI964682A0 (fi) 1996-11-25

Similar Documents

Publication Publication Date Title
NO965012L (no) Farmasöytisk preparat som omfatter glukagon
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DK0921812T4 (da) Insulinpræparater, som indeholder et halogenid
DK0610487T3 (da) Nye aminosyrederivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
NO965298L (no) Ny krystallmodifikasjon av CDCH, fremgangsmåte for fremstilling derav og farmasöytiske preparater inneholdende denne
DK58387D0 (da) Farmaceutiske praeparatformer til stabilisering af interferon-alfa, deres anvendelse og fremgangsmaade til deres fremstilling
ES2009216A6 (es) Metodo de preparar un derivado de interleucina-lalfa.
FI963679L (fi) Stabiloitu koostumus peptidien antamiseksi suun kautta
DK0648779T3 (da) 11-benzaldoxim-17beta-methoxy-17alfa-methoxymethyl-estradien-derivater, fremgangsmåder til deres fremstilling og lægemidler indeholdende disse forbindelser
DK1014948T3 (da) Lyofiliseret farmaceutisk præparat som er beregnet til at efterligne et lægemiddel på basis af proteiner eller polypeptider
NO992998D0 (no) Nye analoger av camptotecin, anvendelse som medikamenter og farmas°ytiske blandinger som inneholder disse
DE3866045D1 (de) Arzneimittel zur behandlung von uraemie.
DK370586A (da) N-(4-piperidyl)benzamid-forbindelser, 1-substituerede 4-aminopiperidiner til anvendelse som udgangsmateriale ved deres fremstilling og farmaceutiske praeparater
DK165975C (da) 3-(substitueret amino)-carbonylderivater af 2,2,5,5-tetramethylpyrrolin eller -pyrrolidin og farmaceutisk acceptable salte deraf, fremgangsmaade til deres fremstilling, antiarrhytmisk farmaceutisk praeparat indeholdende dem og fremgangsmaade til praeparatets fremstilling
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
FI963440L (fi) Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset
DK156004C (da) Fremgangsmaade til stabilisering af prostacyclinforbindelser
DK0583338T3 (da) Fremgangsmåde til syntese af peptider, hidtil ukendte aminosyrederivater anvendt i denne fremgangsmåde og fremgangsmåder til deres fremstilling
DK190589A (da) Quinolin-3-carboxylsyreforbindelser, fremgangsmaade til fremstilling heraf og farmaceutisk middel omfattende samme
NO920050L (no) Trifluormetyl-1-karba(1-detia)cefemer
NO974846L (no) Fremgangsmåte for fremstilling av Form 1 Ranitidin-Hydroklorid
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
KR970701559A (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물(stabilized composition for oral administration of peptides)
DK174885D0 (da) Derivater af n-(3-phenylmethylthio-1-oxopropyl)-aminoeddikesyre i form af enantiomere eller blandinger, fremgangsmaade til fremstilling af forbindelserne og laegemiddel indeholdende disse
ITMI930311A0 (it) Composizioni farmeceutiche di derivati amminoacidi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application